Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Neurimmune
Biotech
Royalty pens $425M deal for slice of AstraZeneca ATTR drug sales
Royalty Pharma has secured a stake in another transthyretin-mediated amyloidosis drug.
James Waldron
Jul 22, 2026 10:01am
AZ's latest amyloidosis pact with Neurimmune could reach $780M
Dec 4, 2025 8:00am
AstraZeneca picks up new weapon in fight with Alnylam and Pfizer
Jan 7, 2022 8:20am
Neurimmune’s anti-SOD1 antibody shows promise in ALS mice
Dec 5, 2018 3:30pm
Neurimmune, TVM set up ALS biotech, secure Lilly support
Dec 7, 2016 7:21am
